FI963164L - Diabeteksen vastaisia peptidejä ja menetelmä - Google Patents
Diabeteksen vastaisia peptidejä ja menetelmä Download PDFInfo
- Publication number
- FI963164L FI963164L FI963164A FI963164A FI963164L FI 963164 L FI963164 L FI 963164L FI 963164 A FI963164 A FI 963164A FI 963164 A FI963164 A FI 963164A FI 963164 L FI963164 L FI 963164L
- Authority
- FI
- Finland
- Prior art keywords
- antidiabetic
- peptides
- antidiabetic peptides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/195,963 US6113903A (en) | 1989-03-21 | 1994-02-14 | Peptides and methods against diabetes |
PCT/US1995/001572 WO1995021623A1 (en) | 1994-02-14 | 1995-02-10 | Peptides and methods against diabetes |
Publications (2)
Publication Number | Publication Date |
---|---|
FI963164A0 FI963164A0 (fi) | 1996-08-13 |
FI963164L true FI963164L (fi) | 1996-10-07 |
Family
ID=22723558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI963164A FI963164L (fi) | 1994-02-14 | 1996-08-13 | Diabeteksen vastaisia peptidejä ja menetelmä |
Country Status (10)
Country | Link |
---|---|
US (1) | US6113903A (fi) |
EP (1) | EP0744956A1 (fi) |
JP (1) | JPH10501210A (fi) |
KR (1) | KR100280220B1 (fi) |
AU (1) | AU690234B2 (fi) |
CA (1) | CA2182978A1 (fi) |
FI (1) | FI963164L (fi) |
NO (1) | NO963366L (fi) |
NZ (1) | NZ282118A (fi) |
WO (1) | WO1995021623A1 (fi) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997008303A1 (en) * | 1995-08-30 | 1997-03-06 | University Technologies International Inc. | Transgenic animals expressing diabetogenic t-cell receptor transgenes |
US6054292A (en) * | 1997-07-18 | 2000-04-25 | Incyte Pharmaceuticals, Inc. | T-cell receptor protein |
AU5984701A (en) * | 2000-05-12 | 2001-11-20 | Univ Oregon Health & Science | Method of treating immune pathologies with low dose estrogen |
US7462486B2 (en) * | 2000-05-12 | 2008-12-09 | Oregon Health & Science University | Methods of selecting T cell receptor V peptides for therapeutic use |
US7790690B2 (en) | 2000-10-11 | 2010-09-07 | U.S. Department Of Veterans Affairs | Glucose sensitive regulator of insulin transcription |
US20030100056A1 (en) * | 2000-12-22 | 2003-05-29 | Anneli Attersand | Protein cluster II |
EP1786465A4 (en) * | 2004-07-30 | 2009-01-21 | Univ Oregon Health & Science | METHODS FOR DETECTION AND TREATMENT OF AUTOIMMUNE DISORDERS |
US7375211B2 (en) * | 2005-11-18 | 2008-05-20 | Kou Zhong C | Method for detection and quantification of T-cell receptor Vβ repertoire |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4066510A (en) * | 1976-05-24 | 1978-01-03 | Massachusetts Institute Of Technology | Assay for mutagenesis in diploid human lymphoblasts |
US4544632A (en) * | 1981-06-12 | 1985-10-01 | Yuichi Yamamura | Human T cell lines and method of producing same |
US4647535A (en) * | 1981-08-12 | 1987-03-03 | Research Corporation | Human nonsecretory plasmacytoid cell line |
US4886743A (en) * | 1985-04-24 | 1989-12-12 | California Institute Of Technology | Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof |
EP0616811A1 (en) * | 1985-12-03 | 1994-09-28 | T Cell Sciences, Inc. | Cell-free T cell antigen receptor and its clinical utilities |
US5112735A (en) * | 1987-06-22 | 1992-05-12 | University Of Vermont | Detection of lymphocyte amplification |
WO1989006968A1 (en) * | 1988-02-03 | 1989-08-10 | Xoma Corporation | Therapeutic use of anti-t cell immunotoxin for autoimmune diseases |
FI891226L (fi) * | 1988-04-28 | 1989-10-29 | Univ Leland Stanford Junior | Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom. |
US5612035A (en) * | 1989-03-21 | 1997-03-18 | The Immune Response Corporation | Vaccination against diseases resulting from pathogenic responses by specific T cell populations |
CA2064077C (en) * | 1989-07-19 | 2002-03-12 | Arthur A. Vandenbark | T cell receptor peptides as therapeutics for autoimmune and malignant disease |
US5614192A (en) * | 1989-07-19 | 1997-03-25 | Connective Therapeutics, Inc. | T cell receptor peptides as therapeutics for immune-related disease |
IL99699A (en) * | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
JPH06507384A (ja) * | 1991-01-22 | 1994-08-25 | ザ イミューン レスポンス コーポレイション | 特定のt細胞群による病理的応答により生じる疾患に対するワクチン投与および方法 |
US5552300A (en) * | 1994-01-13 | 1996-09-03 | T Cell Sciences, Inc. | T cell antigen receptor V region proteins and methods of preparation thereof |
-
1994
- 1994-02-14 US US08/195,963 patent/US6113903A/en not_active Expired - Fee Related
-
1995
- 1995-02-10 NZ NZ282118A patent/NZ282118A/en unknown
- 1995-02-10 KR KR1019960704434A patent/KR100280220B1/ko not_active IP Right Cessation
- 1995-02-10 JP JP7521303A patent/JPH10501210A/ja active Pending
- 1995-02-10 WO PCT/US1995/001572 patent/WO1995021623A1/en not_active Application Discontinuation
- 1995-02-10 EP EP95911631A patent/EP0744956A1/en not_active Ceased
- 1995-02-10 CA CA002182978A patent/CA2182978A1/en not_active Abandoned
- 1995-02-10 AU AU19128/95A patent/AU690234B2/en not_active Ceased
-
1996
- 1996-08-13 FI FI963164A patent/FI963164L/fi unknown
- 1996-08-13 NO NO963366A patent/NO963366L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO1995021623A1 (en) | 1995-08-17 |
AU690234B2 (en) | 1998-04-23 |
NZ282118A (en) | 1998-06-26 |
FI963164A0 (fi) | 1996-08-13 |
EP0744956A1 (en) | 1996-12-04 |
JPH10501210A (ja) | 1998-02-03 |
AU1912895A (en) | 1995-08-29 |
KR100280220B1 (ko) | 2001-02-01 |
NO963366L (no) | 1996-10-14 |
NO963366D0 (no) | 1996-08-13 |
US6113903A (en) | 2000-09-05 |
CA2182978A1 (en) | 1995-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9503005A (pt) | Pneumático e compósito | |
DE69524542D1 (de) | Farbkorrekturverfahren und -vorrichtung | |
FI974494L (fi) | Paikannusmenetelmä ja paikannusjärjestely | |
KR960704093A (ko) | 전극 및 이의 제조방법(electrode and preparation thereof) | |
FI965225L (fi) | Uusia peptidejä | |
FI954980L (fi) | Liitosnauha, liitosmenetelmä ja liitosnauhan käsittävä liitos | |
FI960888L (fi) | Protokadheriiniproteiineja ja niiden käyttö | |
FI961350L (fi) | Hapteenimerkityt peptidit | |
BR9506832A (pt) | N-pirazolilanilinas e n-pirazolilaminopiridinas | |
DE69529223D1 (de) | Prüfverfahren | |
IS4459A (is) | Ný peptíð er hafa ónæmisbreytandi áhrif | |
FI971884A0 (fi) | Tietoliikennemenetelmä ja -järjestely | |
US5547381B1 (en) | Fangs and application thereof | |
FI954499L (fi) | Menetelmä ja analyysi | |
FI951101L (fi) | 5-vinyyli- ja 5-etinyylikinoloni- ja -naftyridonikarboksyylihapot | |
DE69420720D1 (de) | Federspeicherbremszylinder und montageverfahren dafür | |
FI970168A0 (fi) | Peptidejä | |
FI964267A (fi) | Porfosyaniini ja CNC-laajennetut porfyriinit | |
FI942298A0 (fi) | Menetelmä ja sovitelma tilaelementtien siirtämiseksi | |
FI963164L (fi) | Diabeteksen vastaisia peptidejä ja menetelmä | |
FI964363L (fi) | Peptidejä | |
FI972551L (fi) | Päällystyslaite ja menetelmä sitä varten | |
FI962836L (fi) | Psoriasiksen vastaisia peptidejä ja menetelmiä | |
FI960706L (fi) | Uusi proteiini ja menetelmiä proteiinin valmistamiseksi | |
GB9423372D0 (en) | Proteins and their uses |